You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
通化東寶(600867.SH):與上海藥明康德就兩項創新藥簽署技術轉讓合同
格隆匯 06-30 18:36

格隆匯6月30日丨通化東寶(600867.SH)公佈,公司全資子公司東寶紫星(杭州)生物醫藥有限公司(“東寶紫星”)與上海藥明康德新藥開發有限公司(“上海藥明康德”)於2021年6月30日簽署了《THDB130/THDB131一類新藥研發項目技術轉讓合同書》以及《THDB150/THDB151一類新藥研發項目技術轉讓合同書》(以下合稱“技術轉讓合同”)。

合同約定東寶紫星將擁有上述項目產品在全球範圍內的知識產權的所有權以及與之相關的利益,並根據雙方約定負責本項目產品的後續臨牀開發、生產和商業化活動。

通化東寶引入兩款創新藥包括THDB130/THDB131和THDB150/THDB151。據悉,這二個項目產品是用於痛風治療(高尿酸血癥)的一類新藥。THDB130/THDB131希望在臨牀開發過程中,能實現與目前市場上治療方案相比,在安全性上有所突破,為痛風患者提供更加安全有效的治療方案。THDB150/THDB151因其在機制上的特殊優勢,既能抑制黃嘌呤氧化酶,從源頭上減少尿酸產生,又能抑制腎臟尿酸鹽轉運體,加快尿酸排出,從兩種途徑調節血尿酸水平,具有臨牀應用前景。

通化東寶聚焦於糖尿病領域及其他內分泌重要領域的藥物研究與開發,通過抓住國家鼓勵創新藥的歷史機遇,不斷推動公司科技創新,提高新藥研發創新能力。此次與上海藥明康德就痛風領域簽署的二個創新性一類新藥項目技術轉讓合同,標誌着通化東寶開始進入痛風領域,是通化東寶在大內分泌領域的進一步拓展,也是雙方基於前期戰略合作的又一成果落地。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account